More Stories

Informist, Friday, Oct. 17, 2025

MUMBAI – The Nifty Pharma index is likely to remain range-bound due to lack of fresh triggers for the pharmaceutical sector ahead of September quarter earnings in the coming weeks. Investors will look out for the earnings of Dr. Reddy's Laboratories Ltd., which will report its Septemeber quarter earnings on Oct. 24. The Indian pharaceutical market's growth in October is expected to remain muted, similar to the growth in September, when it grew 7.3%. 

"The impact of the recently revised goods and services tax will be negligible due to inverted duty benefits and input tax cost benefits; even if, for a few months, companies might have to take a hit, it will not reflect in earnings of upcoming quarters," said Umesh Laddha, research analyst at Nirmal Bang Equities. 

Laddha pointed out that the recent Coldrif cough syrup controversy, involving the deaths of over 20 children in Madhya Pradesh and Rajasthan, could be a concern for Indian drug makers only if the government imposes stringent laws to adhere to international standards. Any such move by the government will result in huge costs for the makeover of their manufacturing units. 

The Nifty Pharma index is expected to move in a broader range of 22250-2245 levels, said Anshul Jain, technical analyst at Laxmishree Investments and Securities. For the week ended Friday, the Nifty Pharma index ended marginally higher at 22253.75 points. Laurus Labs was the biggest gainer in the index, up nearly 3%, and Alkem Laboratories rose over 1%. Wockhardt declined over 5%, the most among constituents of the Nifty Pharma. 

TOP HEADLINES

* HC notice to Alkem Lab on Alchem Intl plea against bar on using Alchem name
* SC allows Natco Pharma to launch risdiplam drug, junks Roche's plea
* Earnings Outlook: Pressure in US may limit pharma co's Q2 earnings growth
* IPO Alert: Rubicon Research ends 29.5% higher on listing day
* Biocon partners with Civica to commercialise insulin glargine medicine in US
* LIC acquires 17.14 mln shares of Dr Reddy's, raises stake to 10.3% from 8.2%
* Alchem Intl moves HC bench vs bar from using 'Alchem' on Alkem Lab's plea
* IPO Alert: Rubicon Research to list Thu; sets issue price at INR 485
* AstraZeneca Pharma to launch sodium zirconium cyclosilicate powder in Nov
* Roche moves SC against HC allowing Natco Pharma to launch risdiplam drug
* IPO Alert: Rubicon Research offer subscribed 103.90 times as of final day
* Earnings Outlook: India, Europe to lead Dr Reddy's Q2 earnings growth
* Lupin to present phase 1a study data of cancer drug in Berlin on Sunday
* HC bars Alchem Intl from using 'Alchem' name for pdts on Alkem Lab's plea
* US FDA issues one observation for Biocon's mfg unit in Cranbury, New Jersey
* US FDA issues 1 observation to Lupin's US mfg unit post pre-approval checks
* Mankind Pharma to buy women's health portfolio from arm for INR 7.97 bln
* IPO Alert: Rubicon Research's offer subscribed 2.37 times as of second day
* South Africa co Adcock Ingram shareholders OK stake sale to Natco Pharma arm
* US FDA concludes Emcure Pharma Gujarat unit inspection with no observation

Following are the resistance and support levels for the stocks for next week as per calculations by Informist based on their prices on the National Stock Exchange:

End

Reported by P. Madhu Kumar

Edited by Avishek Dutta

For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.

Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.

Informist Media Tel +91 (22) 6985-4000 

Send comments to feedback@informistmedia.com

© Informist Media Pvt. Ltd. 2025. All rights reserved.